915 Eli Lilly and Company $LLY Shares Acquired by BLB&B Advisors LLC

Key Points

• BLB&B Advisors increased its Eli Lilly stake by 8.6% in the third quarter, purchasing 915 additional shares and bringing its holdings to 11,585 shares valued at approximately $13.4 million. Institutional investors own 82.53% of the company.
• Eli Lilly reported strong third-quarter results, with revenue rising 38.6% year over year to $24.4 billion and EPS of $7.48, well above expectations. The company also raised its 2026 revenue forecast to $91 billion–$92 billion, supported by robust Mounjaro and Zepbound demand.
• Analysts remain broadly bullish, with several firms raising price targets and MarketBeat assigning the stock a “Moderate Buy” consensus rating. However, investors face elevated valuation and execution risks, including pricing pressure and heavy reliance on GLP-1 products.

BLB&B Advisors LLC increased its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 8.6% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 11,585 shares of the company's stock after buying an additional 915 shares during the quarter. BLB&B Advisors LLC's holdings in Eli Lilly and Company were worth $13,405,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. AMI Investment Management Inc. increased its holdings in shares of Eli Lilly and Company by 55.2% in the 3rd quarter. AMI Investment Management Inc. now owns 405 shares of the company's stock worth $469,000 after acquiring an additional 144 shares during the period. Sigma Investment Counselors Inc. increased its stake in shares of Eli Lilly and Company by 3.2% in the third quarter. Sigma Investment Counselors Inc. now owns 1,357 shares of the company's stock valued at $1,570,000 after purchasing an additional 42 shares during the period. William Mack & Associates Inc. bought a new stake in shares of Eli Lilly and Company during the third quarter valued at approximately $117,000. Victory Financial Group LLC grew its holdings in Eli Lilly and Company by 8.5% in the 3rd quarter. Victory Financial Group LLC now owns 3,560 shares of the company's stock worth $4,119,000 after buying an additional 279 shares in the last quarter. Finally, Guerra Pan Advisors LLC increased its position in Eli Lilly and Company by 6.9% in the 3rd quarter. Guerra Pan Advisors LLC now owns 403 shares of the company's stock valued at $500,000 after acquiring an additional 26 shares during the period. 82.53% of the stock is currently owned by institutional investors.

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, EVP Patrik Jonsson sold 6,500 shares of Eli Lilly and Company stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the sale, the executive vice president directly owned 54,147 shares of the company's stock, valued at approximately $63,628,139.70. The trade was a 10.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald A. Zakrowski sold 2,000 shares of the firm's stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the transaction, the chief accounting officer owned 1,526 shares of the company's stock, valued at $1,808,325.26. This trade represents a 56.72% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 13,500 shares of company stock valued at $15,958,170. Company insiders own 0.14% of the company's stock.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Q3 results substantially beat expectations. Revenue rose 39% year over year to $24.4 billion, while adjusted EPS was $7.48 versus the $5.68 consensus estimate. Mounjaro sales increased 65% to $10.7 billion and Zepbound sales rose 49% to $5.35 billion. Lilly third-quarter results
• Positive Sentiment: Lilly raised its 2026 revenue forecast to $91 billion-$92 billion, up from $85 billion-$87 billion previously. Strong demand, broader Medicare access and growing middle-income adoption are supporting expectations for continued GLP-1 expansion. Q3 earnings call highlights
• Positive Sentiment: Analysts raised their price targets and maintained bullish ratings. Scotiabank lifted its target to $1,605 with a “sector outperform” rating, Morgan Stanley raised its target to $1,596 with an “overweight” rating, and RBC moved to $1,600 with an “outperform” rating. Analyst commentary
• Positive Sentiment: Pipeline and portfolio diversification offer additional upside. Positive Phase 3 retatrutide data strengthened Lilly’s competitive position against Novo Nordisk, while oncology, immunology and neuroscience products are beginning to contribute more meaningfully. Lilly growth opportunities
• Negative Sentiment: Investors face execution and valuation risks. Realized prices fell 15%, meaning volume growth must continue to offset pricing pressure. Results also benefited from roughly $900 million in one-time items, and acquired in-process research charges weighed on earnings. With GLP-1 drugs representing a large share of revenue and the stock near its high, expectations are elevated. Reuters earnings report

Eli Lilly and Company Stock Performance

Shares of NYSE LLY opened at $1,415.64 on Friday. The business's 50-day simple moving average is $1,197.72 and its 200-day simple moving average is $1,092.57. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.00 and a current ratio of 1.35. Eli Lilly and Company has a 52 week low of $834.19 and a 52 week high of $1,449.68. The firm has a market cap of $1.33 trillion, a price-to-earnings ratio of 45.95, a P/E/G ratio of 1.73 and a beta of 0.46.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its earnings results on Thursday, October 29th. The company reported $7.48 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.71 by $1.77. The business had revenue of $24.40 billion for the quarter, compared to analyst estimates of $22.58 billion. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 93.68%. Eli Lilly and Company's revenue was up 38.6% compared to the same quarter last year. During the same period last year, the business posted $7.02 EPS. As a group, equities research analysts expect that Eli Lilly and Company will post 35.50 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date of this dividend is Friday, November 13th. Eli Lilly and Company's dividend payout ratio (DPR) is presently 23.22%.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on LLY. UBS Group reissued a "buy" rating and set a $1,625.00 price target on shares of Eli Lilly and Company in a report on Friday. Citigroup raised their price objective on shares of Eli Lilly and Company from $1,600.00 to $1,650.00 and gave the company a "buy" rating in a research note on Friday. Argus boosted their target price on Eli Lilly and Company from $1,300.00 to $1,550.00 and gave the stock a "buy" rating in a report on Friday. Wall Street Zen raised Eli Lilly and Company from a "hold" rating to a "buy" rating in a research note on Saturday. Finally, Truist Financial reiterated a "buy" rating and issued a $1,612.00 price target (up from $1,376.00) on shares of Eli Lilly and Company in a research report on Friday. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, Eli Lilly and Company has a consensus rating of "Moderate Buy" and a consensus target price of $1,398.43.

About Eli Lilly and Company

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company's portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.